xBiotech USA, Inc.
8201 E Riverside Drive
Building 4, Suite 100
115 articles about xBiotech USA, Inc.
XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus
The 514G3 antibody was a naturally occurring antibody derived from a healthy individual with highly targeted immunity against S. aureus capable of neutralizing all strains of the bacteria, including a drug-resistant or so-called MRSA form.
XBiotech Announces Presentation of Phase II Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
The findings being presented come from patients that had received placebo in a previous Phase 2 double-blind, placebo-controlled study.
XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology
The publication highlights the efficacy of MABp1, in which the study’s primary endpoint was met in 60% of MABp1 treated patients compared to 10% of placebo patients.
XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions
IL-1a Neutralizing Antibody MABp1 Found to Block NETs’ Ability to Increase Endothelial Activation and Thrombogenicity
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination With Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator.
XBiotech Announces Addition Of Renowned Dermatologist Dr. William Levis To Its Scientific Advisory Board
XBiotech Announces Agreement With Cedars-Sinai Medical Center To Evaluate Mabp1 In Combination With Onivyde? And 5-Fluorouracil/Folinic Acid For The Treatment Of Pancreatic Cancer
XBiotech Announces Presentation Of Phase II Study Data Evaluating Mabp1 For The Treatment Of Hidradenitis Suppurativa
XBiotech Plunged 66% After Discontinuing Phase III Colorectal Cancer Study
XBiotech Presents Phase III Findings For Its Antibody Therapy For Colorectal Cancer At The 2017 ASCO Meeting
XBiotech Sinks To A New Low After The EMA Rejects Lead Drug
Struggling XBiotech Quietly Discloses Exec Resignation
XBiotech To Provide First Quarter 2017 Business Update
XBiotech Craters After Disappointing EMA Meeting
XBiotech Announces Additions To Its Scientific Advisory Board
XBiotech Reports Top-Line Results For 514G3 Antibody Therapy In Serious Staphylococcus Aureus Infections
XBiotech Reports Affirmative Interim Analysis Of Global Phase III Colorectal Cancer Study
XBiotech Completes Dosing Of Subjects In PK Study Being Conducted In Connection With European Marketing Application
XBiotech Provides Update On Xilonix Phase III Programs In U.S. And EU
European Regulator Calls XBiotech's Phase III Cancer Data Unreliable